On the stock market since 2014, it operates in the world of health and science. It has 221 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 58% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 31% below its peak. The market has trimmed its expectations for the company.
There is $622.5M in the vault; even if every debt were paid off, $85.9M would remain.
The average analyst price target is $57.50 — 19% above today’s price.
A loss of $199.0M against $16.1M in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, QURE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: QURE is a small company that closed last year at a loss. The road back to profit runs through spending discipline.